EUVIMEDEUVIMED entdecken
Kommentar

Anti-LAG-3 boosts CD8 T cell effector function

Courtney T Kureshi, Michael Dougan, Stephanie K Dougan

Cell · 2024-08 · 187 (16) · 4144-4146

DOI: 10.1016/j.cell.2024.07.004 ↗

Kurz gefasst

Kommentar in der Zeitschrift Cell, 2024-08. Verfasst von Courtney T Kureshi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Program in Immunology, Harvard Medical School, Boston, M…. Hauptthemen laut MEDLINE: Lymphocyte Activation Gene 3 Protein, CD8-Positive T-Lymphocytes, Antigens, CD. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

LAG-3 is the third immune checkpoint pathway successfully targeted for cancer therapy. Although ineffective as a monotherapy, combination of LAG-3 and PD-1 blockade improves survival from advanced melanoma. In this issue of Cell, two studies in mice and a human clinical trial provide insights on LAG-3 in immune regulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocyte Activation Gene 3 ProteinCD8-Positive T-LymphocytesAntigens, CDHumansAnimalsMiceMelanomaProgrammed Cell Death 1 ReceptorImmune Checkpoint Inhibitors

Substanzen

Lymphocyte Activation Gene 3 ProteinAntigens, CDProgrammed Cell Death 1 ReceptorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Program in Immunology, Harvard Medical School, Boston, MA, USA.
  • Program in Immunology, Harvard Medical School, Boston, MA, USA; Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Program in Immunology, Harvard Medical School, Boston, MA, USA. Electronic address: stephanie_dougan@dfci.harvard.edu.

Zitieren

APA

Kureshi, C. T., Dougan, M., & Dougan, S. K. (2024). Anti-LAG-3 boosts CD8 T cell effector function. Cell, 187(16), 4144-4146. https://doi.org/10.1016/j.cell.2024.07.004

Vancouver

Kureshi CT, Dougan M, Dougan SK. Anti-LAG-3 boosts CD8 T cell effector function. Cell. 2024;187(16):4144-4146. doi:10.1016/j.cell.2024.07.004

BibTeX
@article{Kureshi2024,
  author = {Kureshi, Courtney T and Dougan, Michael and Dougan, Stephanie K},
  title = {Anti-LAG-3 boosts CD8 T cell effector function},
  journal = {Cell},
  year = {2024},
  volume = {187},
  number = {16},
  pages = {4144--4146},
  doi = {10.1016/j.cell.2024.07.004}
}
Kostenlos starten →